Modulation of morphine antinociceptive tolerance and physical dependence by co-administration of simvastatin

Mansouri, Mohammad Taghi; Khodayar, Mohammad Javad; Tabatabaee, Amirhossein; Ghorbanzadeh, Behnam; Naghizadeh, Bahareh

doi:10.1016/j.pbb.2015.08.002

Cited by 28 publications

(18 citation statements)

References 50 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another studies indicated that simvastatin modulates analgesic tolerance and physical dependence in mice (Ghasemi et al, 2015;Mansouri et al, 2015). The data obtained in different studies demonstrates the beneficial effects of atorvastatin in decreasing the nociception and inflammation in animal pain models including writhing test, tail flick test and orofacial formalin test.…”

Section: Discussionmentioning

confidence: 93%

“…Recently, several landmark experimental trials demonstrated the beneficial effects of statin therapy for morphine-induced analgesic tolerance and dependence. Mansouri et al, (2015) reported that simvastatin modulates morphine antinociceptive tolerance and physical dependence. There is evidence indicating that rosuvastatin attenuates the morphine analgesic tolerance .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Atorvastatin attenuates the antinociceptive tolerance of morphine via nitric oxide dependent pathway in male mice

Hassanipour

Amini-Khoei

Shafaroodi

et al. 2016

Brain Research Bulletin

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Atorvastatin attenuates the antinociceptive tolerance of morphine via nitric oxide dependent pathway in male mice

Hassanipour

Amini-Khoei

Shafaroodi

et al. 2016

Brain Research Bulletin

View full text Add to dashboard Cite

“…Among the 611 statin patients, 36% had atorvastatin, 33% simvastatin, 13% rosuvastatin, 12% pravastatin, 5% lovastatin, and 1% other statins. The median daily dose was 20 mg [Q1, Q3: 10, 40] for atorvastatin, 20 mg [20,40] for simvastatin, 10 mg [10,20] for rosuvastatin, 40 mg [20,40] for pravastatin, and 20 mg [20,40] for lovastatin. As shown in Table 1 and Fig.…”

Section: Resultsmentioning

confidence: 99%

Are perioperative therapeutic doses of statins associated with postoperative pain and opioid consumption after hip surgery under spinal anaesthesia?

Saasouh

Leung

Yılmaz

et al. 2017

British Journal of Anaesthesia

View full text Add to dashboard Cite

show abstract

“…Morphine suppresses many types of pain, but tolerance, physical dependence, and unwanted side effects limit its clinical use (Trang et al, 2007). Identification of therapeutic strategies for blocking opioid tolerance and dependence has therefore evolved as an area of intense research interest (Habibi-Asl et al, 2014;Mansouri, et al, 2015;Hassanipour et al, 2016;Hosseinzadeh et al, 2016). Adjunctive pharmacotherapies that combine mechanistically distinct analgesics represent one such approach.…”

Section: Introductionmentioning

confidence: 99%

Slowly Signaling G Protein–Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence

Lin

Dhopeshwarkar

Huibregtse

et al. 2018

Molecular Pharmacology

View full text Add to dashboard Cite

The CB cannabinoid agonist LY2828360 lacked both toxicity and efficacy in a clinical trial for osteoarthritis. Whether LY2828360 suppresses neuropathic pain has not been reported, and its signaling profile is unknown. In vitro, LY2828360 was a slowly acting but efficacious G protein-biased CB agonist, inhibiting cAMP accumulation and activating extracellular signal-regulated kinase 1/2 signaling while failing to recruit arrestin, activate inositol phosphate signaling, or internalize CB2 receptors. In wild-type (WT) mice, LY2828360 (3 mg/kg per day i.p. × 12 days) suppressed chemotherapy-induced neuropathic pain produced by paclitaxel without producing tolerance. Antiallodynic efficacy of LY2828360 was absent in CB knockout (KO) mice. Morphine (10 mg/kg per day i.p. × 12 days) tolerance developed in CBKO mice but not in WT mice with a history of LY2828360 treatment (3 mg/kg per day i.p. × 12 days). LY2828360-induced antiallodynic efficacy was preserved in WT mice previously rendered tolerant to morphine (10 mg/kg per day i.p. × 12 days), but it was absent in morphine-tolerant CBKO mice. Coadministration of LY2828360 (0.1 mg/kg per day i.p. × 12 days) with morphine (10 mg/kg per day × 12 days) blocked morphine tolerance in WT but not in CBKO mice. WT mice that received LY2828360 coadministered with morphine exhibited a trend ( = 0.055) toward fewer naloxone-precipitated jumps compared with CBKO mice. In conclusion, LY2828360 is a slowly signaling, G protein-biased CB agonist that attenuates chemotherapy-induced neuropathic pain without producing tolerance and may prolong effective opioid analgesia while reducing opioid dependence. LY2828360 may be useful as a first-line treatment in chemotherapy-induced neuropathic pain and may be highly efficacious in neuropathic pain states that are refractive to opioid analgesics.

show abstract

Modulation of morphine antinociceptive tolerance and physical dependence by co-administration of simvastatin

Cited by 28 publications

References 50 publications

Atorvastatin attenuates the antinociceptive tolerance of morphine via nitric oxide dependent pathway in male mice

Atorvastatin attenuates the antinociceptive tolerance of morphine via nitric oxide dependent pathway in male mice

Are perioperative therapeutic doses of statins associated with postoperative pain and opioid consumption after hip surgery under spinal anaesthesia?

Slowly Signaling G Protein–Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence

Contact Info

Product

Resources

About